# Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing (IgNGS) in Diffuse Large B Cell Lymphoma (DLBCL)

> **NCT04237168** · — · UNKNOWN · sponsor: **Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau** · enrollment: 30 (estimated)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse

## Interventions

- **DIAGNOSTIC_TEST:** IgNGS from circulating tumor DNA

## Key facts

- **NCT ID:** NCT04237168
- **Lead sponsor:** Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01
- **Primary completion:** 2021-12
- **Final completion:** 2022-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04237168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04237168, "Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing (IgNGS) in Diffuse Large B Cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04237168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*